Relevant bibliographies by topics / Novel COPD Medications

Contents

  1. Journal articles
  2. Book chapters
  3. Conference papers

Academic literature on the topic 'Novel COPD Medications'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Novel COPD Medications.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Novel COPD Medications"

1

Verma, Shiv, Abhishek Chandra, Manisha Gupta, and Manoj Pandey. "Factors contributing in non-adherence to inhaler therapy among patients with obstructive airway diseases in a tertiary care setting." Journal of Medical and Allied Sciences 14, no. 1 (2024): 23. http://dx.doi.org/10.5455/jmas.203694.

Full text
Abstract:
Medication adherence is crucial for managing respiratory conditions effectively. This study aimed to explore the multifaceted factors influencing medication adherence among patients with respiratory illnesses. A comprehensive analysis was conducted, focusing on patient demographics, characteristics, clinical factors, beliefs about medications, and reasons for irregular medication use. A cross-sectional design assessed medication adherence and beliefs in COPD patients through questionnaires. The study identified a middle-aged population (average age: 48.5 years) with high smoking prevalence, al
APA, Harvard, Vancouver, ISO, and other styles
2

Ferrera, Michael C., Wassim W. Labaki, and MeiLan K. Han. "Advances in Chronic Obstructive Pulmonary Disease." Annual Review of Medicine 72, no. 1 (2021): 119–34. http://dx.doi.org/10.1146/annurev-med-080919-112707.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20
APA, Harvard, Vancouver, ISO, and other styles
3

Truong, Lillian, Yun-Min Zheng, and Yong-Xiao Wang. "The Potential Important Role of Mitochondrial Rieske Iron–Sulfur Protein as a Novel Therapeutic Target for Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease." Biomedicines 10, no. 5 (2022): 957. http://dx.doi.org/10.3390/biomedicines10050957.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, which is often due to pulmonary hypertension (PH). The underlying molecular mechanisms are poorly understood, and current medications are neither specific nor always effective. In this review, we highlight the recent findings on the roles of altered mitochondrial bioenergetics in PH in COPD. We also discuss the central role of mitochondrial reactive oxygen species (ROS) generation mediated by Rieske iron–sulfur protein (RISP) and review the contributions of RISP-dependent DNA damage and NF-κB-associated
APA, Harvard, Vancouver, ISO, and other styles
4

Abukwaik, Aya Wail, Rupal Mansukhani, and Mary Barna Bridgeman. "Long-Acting Bronchodilator Use in the Management of Stable COPD." Annals of Pharmacotherapy 52, no. 6 (2017): 562–70. http://dx.doi.org/10.1177/1060028017746697.

Full text
Abstract:
Objective: To review the management of chronic obstructive pulmonary disease (COPD), with a focus on updated information regarding the use of long-acting bronchodilators in the prevention of exacerbations and outcomes associated with this disease. Data Sources: A literature search of the MEDLINE databases through November 2017 was conducted. All published articles regarding use of bronchodilator therapy in the management of COPD were evaluated. References of selected articles, data from poster presentations, and abstract publications were additionally reviewed. Study Selection and Data Extract
APA, Harvard, Vancouver, ISO, and other styles
5

Arshpreet, Kaur. "Evaluating the Effectiveness of Ohtuvayre Regimen Over Albuterol in COPD Management." International Journal of Clinical Science and Medical Research 05, no. 03 (2025): 54–56. https://doi.org/10.5281/zenodo.14959107.

Full text
Abstract:
ABSTRACT : One of the main causes of morbidity and poor health worldwide is Chronic Obstructive Pulmonary Disease (COPD) (World Health Organisation, 2024.). Over the last two decades, inhalation treatments had not advanced very much. Still, the U.S. Food and Drug Administration (FDA)'s recent approval of Ohtuvayre (ensifentrine) has brought a first-inclass inhalation medication combining bronchodilator and anti-inflammatory properties via dual inhibition of phosphodiesterase enzymes PDE3 and PDE4. Many trials have confirmed the usage of the new medicine by showing considerable increases in for
APA, Harvard, Vancouver, ISO, and other styles
6

Antus, Balazs. "Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review." ISRN Pulmonology 2013 (March 13, 2013): 1–11. http://dx.doi.org/10.1155/2013/582807.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide. In addition to generating high healthcare costs, COPD imposes a significant burden in terms of disability and impaired quality of life. Unlike many leading causes of death and disability, COPD is projected to increase in many regions of the world as the frequency of smoking is rising and the population is aging. The pharmacological treatment of COPD includes bronchodilators to relax smooth muscle, such as β2-agonists (salbutamol, terbutaline, and fenoterol, short-acting β2-agonists a
APA, Harvard, Vancouver, ISO, and other styles
7

Shah, Binay Kumar, Bivek Singh, Yukun Wang, Shuanshuan Xie, and Changhui Wang. "Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment." Mediators of Inflammation 2023 (July 6, 2023): 1–15. http://dx.doi.org/10.1155/2023/8840594.

Full text
Abstract:
Most patients diagnosed with chronic obstructive pulmonary disease (COPD) present with hallmark features of airway mucus hypersecretion, including cough and expectoration. Airway mucus function as a native immune system of the lung that severs to trap particulate matter and pathogens and allows them to clear from the lung via cough and ciliary transport. Chronic mucus hypersecretion (CMH) is the main factor contributing to the increased risk of morbidity and mortality in specific subsets of COPD patients. It is, therefore, primarily important to develop medications that suppress mucus hypersec
APA, Harvard, Vancouver, ISO, and other styles
8

Mahmood, Malik Quasir, Shakti D. Shukla, Chris Ward, and Eugene Haydn Walters. "The Underappreciated Role of Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease and Its Strong Link to Lung Cancer." Biomolecules 11, no. 9 (2021): 1394. http://dx.doi.org/10.3390/biom11091394.

Full text
Abstract:
The World Health Organisation reported COPD to be the third leading cause of death globally in 2019, and in 2020, the most common cause of cancer death was lung cancer; when these linked conditions are added together they come near the top of the leading causes of mortality. The cell-biological program termed epithelial-to-mesenchymal transition (EMT) plays an important role in organ development, fibrosis and cancer progression. Over the past decade there has emerged a substantial literature that also links EMT specifically to the pathophysiology of chronic obstructive pulmonary disease (COPD)
APA, Harvard, Vancouver, ISO, and other styles
9

Živanović, Dejan, Jovan Javorac, Dejana Savić, et al. "Adherence, Disease Control, and Misconceptions Related to the Use of Inhalation Therapy in Patients with Obstructive Pulmonary Diseases: A Cross-Sectional Study." Medicina 60, no. 6 (2024): 853. http://dx.doi.org/10.3390/medicina60060853.

Full text
Abstract:
Background and Objectives: Inadequate treatment of asthma and chronic obstructive pulmonary disease (COPD) might have a negative impact on their progression. Inhalation therapy is the cornerstone of pharmacotherapy for these conditions. However, challenges such as low adherence, negative attitudes, and misconceptions about inhaled medications still persist, impeding effective disease management. This study aimed to evaluate adherence, ascertain the level of disease control in asthma and COPD, explore potential misconceptions surrounding inhalation therapy among patients with obstructive lung d
APA, Harvard, Vancouver, ISO, and other styles
10

Lam, Simon W., Charlie Strange, Mark L. Brantly, and James K. Stoller. "A Novel Detection Method to Identify Individuals with Alpha-1 Antitrypsin Deficiency: Linking Prescription of COPD Medications with the Patient-Facing Electronic Medical Record." Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 9, no. 1 (2022): 26–33. http://dx.doi.org/10.15326/jcopdf.2021.0260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Novel COPD Medications"

1

Getahun, Biruk, Abebe Ayalew Bekel, Dessalegn Demeke Ayalew, Melkamu Demewez Gebeye, Dagnachew Zemene, and Erstu Legese Beyene. "Recent Advances in Chronic Obstructive Pulmonary Disease." In COPD - Pathology, Diagnosis, Treatment, and Future Directions. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1003820.

Full text
Abstract:
The prevalent respiratory condition known as chronic obstructive pulmonary disease (COPD) is associated with high morbidity and death. Despite being common, COPD is underdiagnosed, and many individuals are not diagnosed until the condition has advanced clinically. The early physiologic and pathobiologic alterations in COPD have been the focus of recent fundamental scientific and clinical research in an effort to improve diagnosis, provide targets for disease-modifying medication, and identify people most likely to benefit from early intervention. Good communication with COPD patients requires
APA, Harvard, Vancouver, ISO, and other styles
2

Soni, Alok K., Puja Kumari, and Souravh Bais. "HAZARDOUS CHEMICALS INDUCED ACUTE LUNG INJURY: MOLECULAR MECHANISM AND TREATMENT APPROACH WITH NOVEL THERAPY." In Futuristic Trends in Medical Sciences Volume 3 Book 15. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bams15p1ch13.

Full text
Abstract:
Pulmonary toxicants are substances that can cause damage to the respiratory system, including the lungs and airways. These toxicants can come from various sources, such as smoking, pollution, and industrial chemicals. Understanding the effects of pulmonary toxicants is crucial in protecting human health and preventing respiratory diseases. Exposure to these substances may lead to oxidative and inflammatory cascades, that can damage the lungs and cause respiratory problems including lung cancer, asthma, chronic obstructive pulmonary disease (COPD), and emphysema. Exposure may be associated with
APA, Harvard, Vancouver, ISO, and other styles
3

Boyar, Vita. "Innovative Biologic Dressings for Neonatal and Pediatric Wounds." In Wound Healing - New Frontiers and Strategies [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1004845.

Full text
Abstract:
The landscape of neonatal and pediatric care has changed dramatically in the last decade. As more immature and critically ill neonates survive, newer treatments are offered, innovative approaches are tried and novel medications are developed. The growth and capabilities of clinical care have exploded, but with those, new complications in the care of neonatal and pediatric skin have surfaced. The intricacies of neonatal skin development are many. Birth and survival of extremely premature and critically ill infants facilitated the development of wounds of “immaturity” and wounds of “critical ill
APA, Harvard, Vancouver, ISO, and other styles
4

Silva, Giovana Alves Martins da, Richard Alecsander Reichert, Silvia Maria de Freitas Adrião, Amanda Simões Baptista, Maria Luiza de Lima Vasconcelos, and Denise De Micheli. "Levels of substance use among young brazilian adults during the pandemic period by COVID-19." In EMERGING ISSUES RELATED TO THE CORONA VIRUS PANDEMIC (COVID 19). Seven Editora, 2023. http://dx.doi.org/10.56238/emerrelcovid19-010.

Full text
Abstract:
The pandemic caused by the novel coronavirus has brought with it several challenges not only the emergency development of pharmacological measures to cope but also a unique scenario of health, political, economic, and social crisis, not to mention possible effects that are yet to emerge. Given this scenario, the objective of this study was to evaluate the impacts of Covid-19 on the behavior of alcohol and medication use of young Brazilian adults between 18 and 30 years of age in the pandemic period from March 2020 to March 2022. To this end, an online study was conducted in which a questionnai
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Novel COPD Medications"

1

Shah, Vrushank, Usmaan Al-Shehab, Keyur Patel, and Alexander King. "Mesenchymal Stem Cell Therapy for Amyotrophic Lateral Sclerosis." In 27th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2023. https://doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.148_2023.

Full text
Abstract:
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig disease, is a fatal neurodegenerative disease affecting motor neurons in the brain and spinal cord. Progressive muscle weakness, atrophy, and spasticity characterize the condition, which eventually leads to paralysis and respiratory failure. There is currently no cure for ALS, and the standard of care is supportive, with riluzole being the only approved medication that has been shown to slightly slow disease progression (1). However, the use of mesenchymal stem cells (MSCs) in the treatment of ALS is a new area of research in regene
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Novel COPD Medications' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography